RET and cancer: RAS mutations are considered weak as they are common in benign thyroid neoplasms and other cancers, whereas RET, NTRK, and ALK rearrangements, along with mutations in BRAF, EIF1AX, and the TERT promoter, are termed strong and are often associated with malignant tumors.